Megan R. Haymart, MD
Megan Haymart, MD, is Assistant Professor of Medicine in the Division of Metabolism, Endocrinology, and Diabetes (MEND) and Hematology/Oncology. Dr. Haymart completed her medical school and internal medicine residency at Johns Hopkins and prior to her arrival at University of Michigan she went on to complete endocrinology fellowship and two years as faculty at the University of Wisconsin. Dr. Haymartís research interest is in the role of patient, provider, and health system factors in the diagnosis and management and thyroid cancer.
Selected Key Papers
- Haymart MR, Muenz DG, Stewart AK, Griggs JJ, Banerjee M. Disease Severity and Radioactive Iodine Use for Thyroid Cancer. J Clin Endocrinol Metab 2013; Jan 15 [epub ahead of print]. PMID: 23322816
- Schuessler KM, Banerjee M, Yang D, Stewart AK, Doherty GM, Haymart MR. Surgeon Training and Use of Radioactive Iodine in Stage I Thyroid Cancer Patients. Ann Surg Oncol 2012; Dec 6 [epub ahead of print]. PMID:23224826.
- Papaleontiou M, Banerjee M, Yang D, Sisson J, Koenig RJ, Haymart MR. Factors that Influence Radioactive Iodine Use for Thyroid Cancer. Thyroid 2012; Nov 7 [epub ahead of print]. PMID:23134514.
- Haymart MR, Banerjee M, Yang D, Stewart AK, Koenig RJ, Griggs JJ. The role of clinicians in determining radioactive iodine use for low-risk thyroid cancer. Cancer 2013; Jan 15; 119(2):259-65.PMID: 22744940
- Haymart MR, Banerjee M, Stewart AK, Koenig RJ, Birkmeyer JD, Griggs JJ. Use of radioactive iodine for thyroid cancer. JAMA 2011; Aug 17;306(7):721-8. PMID:21846853
- Hughes DT, Haymart MR, Miller BS, Gauger PG, Doherty GM. The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years.Thyroid 2011; Mar;21(3):231-6. PMID:21268762